Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP.
Kinsale TS, Cottrell ML, Li L, Brand R, Gatto G, Luecke E, Norton C, Krovi A, Dumond JB, Rao G, Yeshwante S, Van Horne B, Van Der Straten A, Kashuba ADM, Johnson LM. Kinsale TS, et al. Among authors: brand r. Pharmaceutics. 2024 Jan 30;16(2):201. doi: 10.3390/pharmaceutics16020201. Pharmaceutics. 2024. PMID: 38399255 Free PMC article.
Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.
Gatto GJ, Krovi A, Li L, Massud I, Holder A, Gary J, Mills P, Mitchell J, Luecke E, Demkovich ZR, Heneine W, García-Lerma JG, Marzinke MA, Brand RM, Dobard CW, Johnson LM, Van Der Straten A. Gatto GJ, et al. Among authors: brand rm. Front Pharmacol. 2022 Jul 19;13:923954. doi: 10.3389/fphar.2022.923954. eCollection 2022. Front Pharmacol. 2022. PMID: 35928266 Free PMC article.
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.
McGowan I, Dezzutti CS, Siegel A, Engstrom J, Nikiforov A, Duffill K, Shetler C, Richardson-Harman N, Abebe K, Back D, Else L, Egan D, Khoo S, Egan JE, Stall R, Williams PE, Rehman KK, Adler A, Brand RM, Chen B, Achilles S, Cranston RD. McGowan I, et al. Among authors: brand rm. Lancet HIV. 2016 Dec;3(12):e569-e578. doi: 10.1016/S2352-3018(16)30113-8. Epub 2016 Sep 16. Lancet HIV. 2016. PMID: 27658864 Clinical Trial.
MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel.
Ho K, Dominguez-Islas C, Szydlo D, Edick S, Macagna N, Riddler SA, Brand RM, Jacobson CE, Kramzer L, Kunjara Na Ayudhya RP, Piper J, Marzinke MA, Bauermeister J, Nuttall J, Hillier SL, Hendrix CW. Ho K, et al. Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0081622. doi: 10.1128/aac.00816-22. Epub 2022 Oct 18. Antimicrob Agents Chemother. 2022. PMID: 36255254 Free PMC article. Clinical Trial.
Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.
Else LJ, Dickinson L, Edick S, Zyhowski A, Ho K, Meyn L, Dilly-Penchala S, Thompson B, Shaw V, Khoo S, Brand RM. Else LJ, et al. Among authors: brand rm. J Antimicrob Chemother. 2024 May 17:dkae147. doi: 10.1093/jac/dkae147. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38758205
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV.
Cranston RD, Dezzutti CS, Siegel A, Engstrom J, Shetler C, Richardson-Harman N, Abebe KZ, Back D, Else L, Egan D, Khoo S, Egan JE, Stall R, Williams P, Brand RM, Parikh UM, McGowan I. Cranston RD, et al. Among authors: brand rm. AIDS Res Hum Retroviruses. 2019 Sep;35(9):794-804. doi: 10.1089/AID.2018.0265. Epub 2019 Jul 16. AIDS Res Hum Retroviruses. 2019. PMID: 31146534 Clinical Trial.
1,235 results